Cue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Chronic Spontaneous Urticaria
• Cue Biopharma announced positive results from a Phase 2 clinical trial of its CUE-221 treatment for chronic spontaneous urticaria, a condition causing chronic hives. • The trial results demonstrated that the drug achieved significant efficacy and maintained a favorable safety profile for patients. • These findings suggest a potential new therapeutic option for patients suffering from chronic hives who may not respond to existing treatments.
quiverquant.com